VAR2 Pharma has initiated an ambitious R&D program on development and translation of proprietary antibodies targeting oncofetal chondroitin sulfate modifications in solid tumors. It is the ambition of the company that these antibodies can be deployed in both therapeutic and diagnostic applications across multiple types of human cancers.
Menu